Table 1.
Study | n Total of Patients | Type of Study |
Molecular Alterations | Place of Radon Measurement | Studied Area |
Radon Median Bq/m3 Exposition |
Statistical Significance |
---|---|---|---|---|---|---|---|
Taga et al. [86] Prospective 2012 |
n = 70 | Case control study |
EGFRm ex19/21 (n = 24) | Current home |
Non radon-prone area (Moussuri, USA) |
EGFRm: 46.5 Bq/m3 | Non sig. p = 0.16 |
Ruano-Raviña et al. [87] Retrospective 2016 |
n = 323 | Case control study (subanalysis of previous study) |
EGFRm * (n = 90) ALKr (n = 12) |
Current home |
Radon prone area (Galicia, Spain) |
EGFRm ex19: 216 Bq/m3 EGFRm ex21: 118 Bq/m3 ALKr: 290 Bq/m3 |
Non sig. (p value non-available) |
Mezquita et al. [88] Retrospective 2018 |
n = 116,424 | Ecologic study ** |
EGFRm (n = 13,125) ALKr (n = 2928) BRAFm (n = 2419) HER2m (n = 816) ROS1r (n = 373) KRASm (n = 27,314) |
Current home |
Non-radon prone, Intermediate and radon-prone area (France) |
- | p < 0.0001 |
Mezquita et al. [38] Prospective 2019 |
n = 48 | Cross-sectional study |
EGFR m ^ (n = 36) ALKr (n = 10) BRAFm (n = 2) |
Current home |
Intermediate and radon-prone area (Madrid, Spain) |
EGFRm: 96 Bq/m3 ALKr: 116 Bq/m3 BRAFm: 125 Bq/m3 |
Non sig. p = 0.238 |
Mezquita et al. [89] Retrospective 2021 |
n = 3994 | Ecologic study ** |
EGFRm (n = 468) ALKr (n = 129) BRAFm (n = 89) HER2m (n = 32) KRASm (n = 985) |
Childhood home | Non-radon prone, intermediate and radon-prone area (France) |
EGFRm: 72.49 Bq/m3 ALKr: 80.24 Bq/m3 BRAFm: 73.22 Bq/m3 HER2m: 72.74 Bq/m3 KRASm: 71.79 Bq/m3 |
p = 0.0472 |
Abbreviations: EGFRm, EGFR-mutant; BRAFm, BRAF-mutant; HER2m HER2-mutant; KRASm, KRAS-mutant; ALKr, ALK-rearranged; ROS1r, ROS1-rearranged; ex, exon; Non sig., non-significant; USA, United States of America.* Majority with EGFR exon 19 or 21 mutations; 5 cases were EGFR exon 20 mutations. ^ Including EGFR exon 18, 19 and 21 mutations. ** No radon measurement, estimation of radon exposure according to the National Map (IRSN).